Precision RNA Medicine Core Delivery Unit Enables Breakthrough in Tuberculosis Vaccine Development
A recent Cell publication by Drs. Samuel Vidal and Dan Barouch describes a next-generation mRNA-based tuberculosis (TB) vaccine that surpassed the performance of the century-old BCG vaccine in preclinical studies. The trivalent mRNA–lipid nanoparticle (LNP) vaccine, which combines three newly identified TB antigens, significantly reduced infection rates, bacterial spread, and lung bacterial load in animal models—paving the way for upcoming human clinical trials.
Delivery Unit Technology That Made It Possible
This innovation was made possible through the Delivery Unit of the Precision RNA Medicine (PRM) Core, part of the BIDMC Omics Cores Network, which supported the design, optimization, and production of mRNA–LNP vaccine formulations. Leveraging its expertise in RNA delivery systems and nanoparticle formulation, the Delivery Unit enabled translation of immunogen discovery into a scalable and potent vaccine platform.
If you’re developing RNA-based therapeutics or nanoparticle delivery systems, the PRM Delivery Unit offers the infrastructure and expertise to accelerate your research.